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Antiretroviral therapy has signiﬁcantly evolved in the last decade, with an increasing
number of new drugs and classes. Currently, even heavily experienced patients can be
successfully treated with new regimens. In Brazil, the recent incorporation of some new
antiretroviral drugs made it possible to suppress HIV plasma viremia in most treated
patients, with signiﬁcant beneﬁts in terms of quality of life and survival. However, little has
been  published on outcomes of patients under new drugs-based regimens. We reviewed
the  safety and efﬁcacy of antiretroviral regimens using recently introduced drugs in Bahia.
Our results conﬁrm that patients using darunavir, raltegravir, enfuvirtide, or etravirine pre-alvage therapy sented with a high rate of virological suppression without signiﬁcant adverse events, after
one  year of follow-up.
© 2015 Elsevier Editora Ltda. All rights reserved.ne of the most important problems in the treatment of HIV-
 infected patients has been the development of resistance
o antiretroviral (ARV) drugs. In the early HAART era, patients
xposed to multiple ARV regimens usually presented with a
road spectrum of drug resistance, making it difﬁcult to deﬁne
 fully suppressive ARV regimen. The absence of effective
reatment usually led to disease progression and death.1 The
evelopment of new drugs and classes of ARV dramatically
odiﬁed the scenario of salvage therapy for patients previ-
usly exposed to multiple regimens. Several studies provided
trong evidence that even patients with complex drug resis-
ance proﬁle could be successfully treated with a regimen that
nclude new, active ARV drugs.2–6
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like ritonavir-boosted darunavir (DRV/r), raltegravir (RAL),
etravirine (ETV), and maraviroc (MRV). However, the Brazilian
AIDS Program established several rules to use these new ARV
drugs, which are available only as “third line” options. There
is scarce information on the outcomes of patients treated
with these new drugs/classes in developing countries. In the
present work we evaluated the impact of new drugs use on
viral suppression, and its tolerability by patients with a history
of previous failures to multiple regimens.a Augusto Vianna, SN, Canela, Salvador 40140480, Brazil.
We reviewed the Bahia state’s central pharmacy registry
to identify the ﬁrst patients who used darunavir/ritonavir
(DRV/r), enfuvirtide (ENF), raltegravir (RAL), etravirine (ETV)
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Table 1 – Clinical characteristics of 194 patients who
started an ARV regimen containing new ARV drugs.
N %*
Male gender 90 64.3
Infectious comorbidity 117 47.5
HCV 12 6.9
HBV 12 6.7
HTLV 5 2.8
TB 58 32.6
AIDS deﬁning infection 60 33.9
CMV 9 5.1
HPV 11 6.2
Syphilis 10 5.6
Non-infectious comorbidities
Obesity 6 3.4
Lipoatrophia 21 11.8
Lypodistrophia 35 19.7
Dyslipidemia 12 6.7
Hypertension 22 12.4
Diabetes 14 7.9
Illicit drugs use 20 14.8
Alcohol 55 36.5
when compared to baseline values (p = 0.04). No signiﬁcantSmoking 38 25.2
or maraviroc (MVC) up to August 2011. After identiﬁcation of
all patients who  used or were in use of these ARV drugs, we
reviewed the medical records to evaluate clinical character-
istics, virological response, and tolerability of ARV regimens
containing these new drugs.
We compared CD4 counts and plasma HIV-1 RNA viral loads
at the moment of initiation of ARV regimens containing one or
more  of these new drugs, and 6 and 12 months thereafter. The
proportion of patients with undetectable viral load was com-
pared at each time-point, as well as the change in CD4 count.
Adherence to therapy was also evaluated, and the frequency
of adverse events was recorded.
Mean age for patients included in this study was 41.2 ± 11.9
years. Around two-thirds (60%) were male, and black/racially
mixed (68%). Only 17% described themselves as white, while
15% were of other ethnic groups. The mean number of previ-
ous ARV regimens was 4.8 ± 3.3. Mean HIV-1 RNA plasma viral
load was 4.6 ± 1.3 log copies/mL, while mean CD4+ cell count
was 273 ± 32 cells/mm3. As expected in a subpopulation of
patients with long-term treatment history, most of them had
a previous diagnosis of infectious and non-infectious comor-
bidities. Table 1 shows the main health problems detected in
this population.
Table 2 – Number of medical prescriptions for new drugs in the
Drug Number
RAL (%) DRV/R (%) 
RAL 143 (51.8) 111 (40.2) 
DRV/r 111 (40.2) 79 (33.3) 
ENF 17 (46.3) 6 (15.4) 
ETV 05 (26.3) 6 (31.6) 
Total 276 (50.5) 212 (38.8)  1 5;1  9(5):529–532
We  identiﬁed a total of 546 medical prescriptions of at
least one of these new ARV, distributed between the four
referral centers in Salvador city, Bahia, Brazil, and several
smaller cities in Bahia. Table 2 summarizes the number of
prescriptions of each ARV drug. Due to the limited access
to medical charts from other institutions, we  focused the
review on medical records of two main referral centers for
AIDS care in Bahia, namely Centro de Ensino, Diagnóstico,
Assistencia e Pesquisa (CEDAP) and Complexo Hospitalar Prof.
Edgard Santos (C-HUPES), at the Federal University of Bahia
Hospital. Together, these two institutions concentrate about
two-thirds of the total number of patients in the state. Thus,
a total of 246 patients had their records selected for review.
However, 52 of them were excluded, because their medical
charts were incomplete, with many  missing information. The
remaining 194 (79%) patients were included in this analy-
sis. Of note, only 15 (6%) patients were in use of three new
ARV (DRV/r + RAL + ETV in nine cases, RAL + DRV/r + ENF in six
cases).
After six months of therapy with the new drugs 71.1% of
patients had HIV-1 RNA plasma viral load below the limit
of detection (50 copies/mL), and after 12 months this rate
increased to 74.7%. Mean CD4+ cell count at month six was
377 ± 274 cells/mm3 (net gain from baseline of 104 cells/m3),
raising to 476 ± 282 cells after 12 months (additional gain of
99 cells/mm3, p < 0.001 for both values, compared to base-
line). Mean HIV-1 RNA plasma viral load (log10 copies/mL)
was 4.6 ± 1.3 at baseline, decreased to 1.7 ± 1.2 at six months,
and to 1.7 ± 1.2 at 12 months (p < 0.001 for comparison with
baseline values for both time-points). Table 3 details lab-
oratory characteristics of patients at diagnosis, at therapy
baseline, and 6/12 months after salvage regimen had been
introduced.
The main adverse events reported by patients are summa-
rized in Table 4. Of note, gastrointestinal complaints were the
most commonly detected problems: nausea or diarrhea was
reported by 10.7% of patients. Local pain, the most frequent
adverse event related to ENF, was detected in 20/39 (64%) of
patients on ENF. Optimal (100%) self-reported adherence rate
to new ARV regimen was 71%. Laboratory parameters were
similar after six and 12 months, compared to baseline values,
except for creatinine (variation from 0.9 to 1.0 after six months
and from 1.0 to 1.1 after 12 months, (p < 0.01 for comparison
of both time-points with baseline), and for HDL cholesterol,
which showed a mean decrease of 4 mg  at six and 12 monthsvariations were observed in liver enzymes, lipids other than
HDL cholesterol, hemoglobin or glucose.
 study’s period.
 of prescriptions for each drug
ENF (%) ETV (%) Total
17 (6.1) 5 (1.8) 276 (100)
06 (2.8) 06 (2.8) 212 (100)
16 (41.0) 0 39 (100)
0 8 (42.1) 19 (100)
39 (7.1) 19 (3.5) 546 (100)
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Table 3 – Mean HIV-1 RNA plasma viral load (PVL) and CD4/8 count at baseline, pre-therapy, and 6/12 months post
therapy with new drugs.
Mean SD Minimum Maximum Percentiles
25 Median 75
First evaluation (at diagnosis)
PLV (log10) 4.73 1.16 1.00 6.99 4.09 4.88 5.56
CD4 (cells/mm3) 276 320 4 2140 56 168 334
CD8 (cells/mm3) 966.9 587.6 51 2556 458 854 1345
Evaluation before introduction of new drugs
PVL (log10) 3.67 1.65 1.00 6.00 2.41 4.30 4.93
CD4 (cells/mm3) 377 274 2 1300 101 242 429
CD8 (cells/mm3) 938.8 599.2 108 2839 514 784 1234
Evaluation after 6 months under new drugs regimen
PVL (log10) 1.73 1.31 1.00 5.64 1.00 1.00 1.99
CD4 (cells/mm3) 394.2 247.7 19 1270 212 338 530
CD8 (cells/mm3) 1145.8 590.4 72 3018 761 1065 1375
Evaluation after 12 months under new drugs regimen
PVL (log10) 1.81 1.44 1.00 5.29 1.00 1.00 2.54
CD4 (cells/mm3) 448.0 272.9 2 1592 295 398 569
CD8 (cells/mm3) 1263.6 601.0 133 2958 782 1182 1777
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dp < 0.05 for comparisons between CD4 and viral load at baseline (time
Forty-seven patients (19%) had their ARV regimens
hanged, after starting a regimen containing at least one new
rug. In 21 cases, switch was motivated by adverse events, but
irological failure also contributed to regimen change in 20
atients. The remaining six patients had discontinued therapy
or other reasons.
Virological response to ART regimens including new
ntiretroviral drugs/classes for salvage therapy was very
igh (72%), as evaluated after six months of therapy. This
igh response rate even increased (79%) after 12 months of
ollow-up, demonstrating great virological efﬁcacy in heav-
ly experienced patients. Moreover, the new regimens were
ell tolerated, and adherence level was high, which certainly
ontributed to these responses.
Most of the patients received ARV regimens based on the
se of RAL and/or DRV/r, a minority being treated with reg-
mens including ETV or ENF. DRV/r plus RAL was the most
58%) used regimen, with/without a third new drug. The main
ide-effect observed was reaction at the local of ENF injection,
ollowed by gastrointestinal symptoms (nausea/vomiting or
iarrhea).
Table 4 – Frequency of adverse events among patients in
use of new antiretroviral drugs.
Adverse events (>3%) N %
Nausea/vomiting 13 10.7
Diarrhea 13 10.7
Local pain 25 20.3
Headache 10 8.2
Astenia 4 3.3
Myalgia 6 4.9
Dizziness 6 4.9
Sleep changes 4 3.3
Other 45 23.2
Optimal adherence (self-report) 63 71.6gimen change) and either 6 months/12 months values.
The initial regimens used for salvage therapy were based in
only one new, active drug (usually a PI), and resulted in modest
outcomes, as it was observed in TORO (ENF), POWER (DRV/r)
and RESIST (TPV/r) trials.6–9 Availability of more  recent ARV
dramatically changed this scenario. The BENCHMARK trial
provided rates of up to 80% success at six months, when at
least two new drugs were used.6 Also, there has been a pre-
vious trial showing high response rates with DRV/r and ETV,
and recent studies showing rates close to 100% in salvage ther-
apy of patients treated with a combination of three new drugs,
from different classes.10–12
In Brazil, three previous studies evaluated the effective-
ness of DRV/r-based salvage regimens for highly experienced
patients and found similar results after 48 weeks. Vidal et al.
prospectively followed 92 patients who received a DRV/r-based
ARV salvage regimen, and reported 83% virological suppres-
sion rate.13 Another group published two additional papers,
with a similar approach with rates of virological suppression of
73 and 78%.14,15 All of these studies followed a common strat-
egy (DRV/r-based regiments plus optimized backbone) with
very close results to those found in our study.
Currently, the availability of a large number of ARV drugs
makes it possible to choose the best regimen for treating
experienced patients failing therapy, with a high likelihood
of sustainable virological response. In addition, the newer
classes have also a very good safety proﬁle, reducing the risks
of lower adherence/lower response due to adverse events.11
In conclusion, the real life experience here described
demonstrates that virological response of heavily pre-treated
patients can be as high as that found in clinical trials. The
use of newer drugs and classes makes it easier to treat such
patients, who present with highly resistant HIV-1 strains, in
comparison to the early HAART era. In addition, the favorable
safety proﬁle of these drugs ensures a high level of adherence
to therapy, with no signiﬁcant clinical or laboratory abnormal-
ities.
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